Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Citius Pharmaceuticals Inc (NQ: CTXR )

0.9000 USD -0.0250 (-2.70%)
Streaming Delayed Price Updated: 3:38 PM EST, Nov 24, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 588,369
Open 0.9179
Bid (Size) 0.8998 (3)
Ask (Size) 0.9000 (20)
Prev. Close 0.9250
Today's Range 0.8729 - 0.9179
52wk Range 0.4000 - 1.970
Shares Outstanding 10,677,222
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Citius Pharmaceuticals to Present at Virtual Fall Investor Summit
Mino-Lok, Company's lead product, is progressing through Phase 3 trials and to be positioned for market entry into an estimated $1.5 billion market 
From PR Newswire
Citius Pharmaceuticals to Present at H.C. Wainwright 6th Annual Israel Conference
Anticipates response on pre-investigational new drug (PIND) guidance from the FDA in November 2020 to proceed with Clinical Development Program for Mino-Wrap 
From PR Newswire

Performance

YTD
-9.18%
-9.18%
1 Month
-11.76%
-11.76%
3 Month
-5.26%
-5.26%
6 Month
+3.45%
+3.45%
1 Year
+95.61%
+95.61%

More News

Read More
Creative Contactless Disinfection Solutions Arise in a Time of Need
From PR Newswire
Citius Pharmaceuticals Issues October 2020 Letter to Shareholders
From PR Newswire
Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) and Other Acute Respiratory Conditions
From PR Newswire
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acut
From PR Newswire
Citius's Mino-Lok trial sites resupplied with registration batch product
From PR Newswire
Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial
From PR Newswire
Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok®
From PR Newswire
Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance
From PR Newswire
Citius Pharmaceuticals to Present at H.C. Wainwright Virtual 22nd Annual Global Investment Conference
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.